HeartBeam Inc. (NASDAQ: BEAT) has reported second-quarter 2026 financial and operational results, highlighting significant strides in its heart attack detection program and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, it surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, a key step toward validating its technology for detecting acute coronary syndrome.
The company also completed a working prototype of its 12-lead ECG extended wear patch, signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients. These milestones indicate that HeartBeam is transitioning from development to commercialization, aiming to provide portable, cable-free ECG monitoring that synthesizes 3D signals into a 12-lead ECG, potentially enabling early detection of heart attacks outside medical facilities.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per share, consistent with the prior year's loss. Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. The company expects full-year 2026 net operating cash outflow to be below $14 million, and it has extended its cash runway into 2027, providing sufficient capital to fund ongoing clinical trials and commercialization efforts.
The importance of these developments lies in the potential to improve outcomes for heart attack patients. Traditional 12-lead ECGs are typically available only in medical settings, delaying diagnosis. HeartBeam's technology aims to synthesize a 12-lead ECG from a portable device, allowing patients to record cardiac signals anywhere and transmit them to physicians for analysis. This could enable earlier detection and treatment, potentially saving lives and reducing healthcare costs.
HeartBeam's platform has received FDA clearance for arrhythmia assessment and for its 12-lead ECG synthesis software, and the company holds over 20 issued patents. The ongoing ALIGN-ACS and HEADSTART-ACS studies are designed to support expanded indications for heart attack detection, which could significantly broaden the addressable market.
With its cash runway extended into 2027, HeartBeam is well-positioned to execute its strategic plan. The company's progress in both clinical development and commercial rollout suggests it is on track to become a key player in cardiac monitoring. Investors and healthcare professionals alike will be watching closely as the data from these studies are presented and as the product reaches more patients.
